TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer.

ABSTRACT:

Background

Pancreatic cancer is a highly aggressive malignancy with limited treatment options and a poor prognosis. Trophoblast cell surface antigen 2 (TROP2), a cell surface antigen overexpressed in the tumors of more than half of pancreatic cancer patients, has been identified as a potential target for antibody-drug conjugates (ADCs). Almost all reported TROP2-targeted ADCs are of the IgG type and have been poorly studied in pancreatic cancer. Here, we aimed to develop a novel nanobody-drug conjugate (NDC) targeting TROP2 for the treatment of pancreatic cancer.

Results

In this study, we developed a novel TROP2-targeted NDC, HuNb_TROP2-HSA-MMAE, for the treatment of TROP2-positive pancreatic cancer. HuNb_TROP2-HSA-MMAE is characterized by the use of nano

SUBMITTER: Xu C 

PROVIDER: S-EPMC10629078 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature